Danaher (NYSE:DHR) Now Covered by Scotiabank

Analysts at Scotiabank began coverage on shares of Danaher (NYSE:DHRGet Free Report) in a report released on Monday. The firm set a “sector perform” rating on the conglomerate’s stock.

Other research analysts have also recently issued research reports about the stock. Royal Bank of Canada decreased their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. KeyCorp boosted their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus upped their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research note on Thursday, October 31st. Finally, Robert W. Baird dropped their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $288.21.

Read Our Latest Analysis on DHR

Danaher Price Performance

NYSE:DHR opened at $228.55 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher has a 1 year low of $222.53 and a 1 year high of $281.70. The firm has a market capitalization of $165.08 billion, a price-to-earnings ratio of 43.62, a PEG ratio of 4.33 and a beta of 0.83. The business has a 50 day simple moving average of $243.07 and a 200-day simple moving average of $256.44.

Danaher (NYSE:DHRGet Free Report) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter last year, the business posted $2.02 EPS. Equities analysts forecast that Danaher will post 7.5 EPS for the current year.

Institutional Trading of Danaher

Several institutional investors have recently modified their holdings of the company. nVerses Capital LLC acquired a new position in Danaher in the 2nd quarter worth approximately $25,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher in the 3rd quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher in the third quarter worth $40,000. FSA Wealth Management LLC bought a new stake in Danaher during the third quarter valued at about $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter valued at approximately $55,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

About Danaher

(Get Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Recommended Stories

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.